UPDATE : Thursday, June 4, 2020
Regulator OKs Genematrix's acute enteritis detection kit
  • By Lee Han-soo
  • Published 2020.03.30 17:22
  • Updated 2020.03.30 17:22
  • comments 0

Genematrix said that it has received approval from the Ministry of Food and Drug Safety for NeoPlex GI-Virus6 Detection kit, an acute enteritis diagnostic device.

Genematrix's acute enteritis diagnostic kit NeoPlex GI-Virus6

The main feature of this device is that it can perform multiple tests on the digestive tract virus at once, the company said. The kit also can detect a total of six viruses, such as the rotavirus, gastrointestinal adenovirus, and norovirus, it added.

"The kit can quickly and accurately test a large number of infectious agents in a single process, thereby minimizing unnecessary tests and shortening the patient's hospital stay," Genematrx said. "More than 70 percent of the cases of pathogens causing acute enterocolitis have been reported as viruses. As communal feeding, such as group meals, delivery services and convenience meals, have increased, infection cases also rose."

Some early symptoms of the disease, including fever, diarrhea, vomiting, nausea, and anorexia, are similar to respiratory infection diseases such as COVID-19 or flu virus.

Therefore, the company stressed, early diagnosis is essential for prompt and accurate screening,

"With the regulator’s approval, we have secured a complete lineup for diagnostic kits comprising sexually transmitted diseases, respiratory infection, and digestive diseases test products," a company official said.

Among the various molecular diagnostic fields, the company focused on the areas with the highest growth potential and high product demand, and applied the company's original technology C-tag to secure product competitiveness, the official noted.

The company will be able to expand local and overseas sales by differentiating its products targeting multiplex consumers, he added.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top